4170
Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It is involved in cell preparation product manufacturing; and collection and storage of immune cells. The company's products are used in the field of infectious diseases and inflammation, cancer, oncology. Vectorite Biomedical Inc. was incorporated in 2004 and is based in New Taipei C… Read more
4170 (4170) - Total Liabilities
Latest total liabilities as of June 2025: NT$23.62 Million TWD
Based on the latest financial reports, 4170 (4170) has total liabilities worth NT$23.62 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
4170 - Total Liabilities Trend (2019–2024)
This chart illustrates how 4170's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
4170 Competitors by Total Liabilities
The table below lists competitors of 4170 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BCM Resources Corporation
PINK:BCMRF
|
USA | $483.45K |
|
Dongil Metal Co. Ltd
KQ:109860
|
Korea | ₩24.74 Billion |
|
Associated Industries China Inc
TW:9912
|
Taiwan | NT$422.00 Million |
|
Koil Energy Solutions Inc.
OTCQB:KLNG
|
USA | $11.16 Million |
|
Netgem SA
PA:ALNTG
|
France | €13.72 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down 4170's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.06 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 4170's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 4170 (2019–2024)
The table below shows the annual total liabilities of 4170 from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$23.20 Million | +9.16% |
| 2023-12-31 | NT$21.25 Million | -13.22% |
| 2022-12-31 | NT$24.49 Million | -4.74% |
| 2021-12-31 | NT$25.71 Million | +7.10% |
| 2020-12-31 | NT$24.00 Million | -50.88% |
| 2019-12-31 | NT$48.87 Million | -- |